Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of myocardial damage in PCI
IRCT20221102056378N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in cardiac morbidity and Myocardial injury, sponsored by Tabriz University of Medical Sciences. Started Nov 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
cardiac morbidityMyocardial injury
Beyond the preview
Go deeper on IRCT20221102056378N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221102056378N1.